Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice.
Keisuke KazamaManabu ShiozawaMasakatsu NumataNobuhiro SuganoSumito SatoMamoru UchiyamaMaho SatoToru AoyamaHiroshi TamagawaTakashi OshimaNorio YukawaYasushi RinoPublished in: International journal of colorectal disease (2021)
We found that M-FOLFOXIRI + BV had more favourable efficacy and safety than O-FOLFOXIRI + BV, which may be a better fit for Asian patients and can be potentially used as an alternative for upfront chemotherapy for mCRC.
Keyphrases
- metastatic colorectal cancer
- end stage renal disease
- clinical practice
- lipopolysaccharide induced
- ejection fraction
- newly diagnosed
- chronic kidney disease
- lps induced
- peritoneal dialysis
- prognostic factors
- electronic health record
- squamous cell carcinoma
- inflammatory response
- big data
- machine learning
- locally advanced